Search Results for: Influenza

856 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
CLTC and GGA1 clathrin heavy chain golgi associated, gamma adaptin ear containing, ARF binding protein 1
  • Entry of Influenza Virion into Host Cell via Endocytosis
  • Retrograde neurotrophin signalling
  • Retrograde neurotrophin signalling
  • Gap junction degradation
  • Formation of annular gap junctions
  • MHC class II antigen presentation
  • EPH-ephrin mediated repulsion of cells
  • Lysosome Vesicle Biogenesis
  • Recycling pathway of L1
  • Recycling pathway of L1
  • WNT5A-dependent internalization of FZD4
  • WNT5A-dependent internalization of FZD2, FZD5 and ROR2
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • VLDLR internalisation and degradation
  • LDL clearance
  • TBC/RABGAPs
  • Amyloid fiber formation
CLTC and XRCC6 clathrin heavy chain X-ray repair cross complementing 6
  • Entry of Influenza Virion into Host Cell via Endocytosis
  • Retrograde neurotrophin signalling
  • Retrograde neurotrophin signalling
  • Gap junction degradation
  • Formation of annular gap junctions
  • MHC class II antigen presentation
  • EPH-ephrin mediated repulsion of cells
  • Lysosome Vesicle Biogenesis
  • Recycling pathway of L1
  • Recycling pathway of L1
  • WNT5A-dependent internalization of FZD4
  • WNT5A-dependent internalization of FZD2, FZD5 and ROR2
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • VLDLR internalisation and degradation
  • LDL clearance
  • 2-LTR circle formation
  • Cytosolic sensors of pathogen-associated DNA
  • IRF3-mediated induction of type I IFN
  • Nonhomologous End-Joining (NHEJ)
  • Neutrophil degranulation
CLTC and SNX5 clathrin heavy chain sorting nexin 5
  • Entry of Influenza Virion into Host Cell via Endocytosis
  • Retrograde neurotrophin signalling
  • Retrograde neurotrophin signalling
  • Gap junction degradation
  • Formation of annular gap junctions
  • MHC class II antigen presentation
  • EPH-ephrin mediated repulsion of cells
  • Lysosome Vesicle Biogenesis
  • Recycling pathway of L1
  • Recycling pathway of L1
  • WNT5A-dependent internalization of FZD4
  • WNT5A-dependent internalization of FZD2, FZD5 and ROR2
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • VLDLR internalisation and degradation
  • LDL clearance
  • Golgi Associated Vesicle Biogenesis
COL1A1 and MMP9 collagen type I alpha 1 chain matrix metallopeptidase 9
  • GPVI-mediated activation cascade
  • Collagen degradation
  • Collagen degradation
  • Extracellular matrix organization
  • Collagen biosynthesis and modifying enzymes
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Assembly of collagen fibrils and other multimeric structures
  • Cell surface interactions at the vascular wall
  • Integrin cell surface interactions
  • Integrin cell surface interactions
  • Anchoring fibril formation
  • Crosslinking of collagen fibrils
  • Syndecan interactions
  • Non-integrin membrane-ECM interactions
  • ECM proteoglycans
  • ECM proteoglycans
  • Scavenging by Class A Receptors
  • GP1b-IX-V activation signalling
  • Platelet Adhesion to exposed collagen
  • Platelet Adhesion to exposed collagen
  • Platelet Aggregation (Plug Formation)
  • MET activates PTK2 signaling
  • RUNX2 regulates osteoblast differentiation
  • Collagen chain trimerization
  • Signaling by SCF-KIT
  • Collagen degradation
  • Collagen degradation
  • Degradation of the extracellular matrix
  • Degradation of the extracellular matrix
  • Activation of Matrix Metalloproteinases
  • Assembly of collagen fibrils and other multimeric structures
  • EPH-ephrin mediated repulsion of cells
  • Interleukin-4 and Interleukin-13 signaling
  • Neutrophil degranulation
  • Extra-nuclear estrogen signaling
  • Collagenase clostridium histolyticum
  • Halofuginone
  • Glutathione
  • Marimastat
  • Minocycline
  • Captopril
  • Glucosamine
  • Zinc
  • 2-Amino-N,3,3-Trimethylbutanamide
  • 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid
  • AE-941
  • PG-530742
  • 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE
  • (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE
  • (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID
  • Ehlers-Danlos syndrome (EDS), including: EDS classical type (EDS1/2); EDS hypermobility type (EDS3); EDS vascular type (EDS4); EDS kyphoscoliosis type (EDS6); EDS arthrochalasia type (EDS7A/7B); EDS dermatospraxis type (EDS7C); EDS autosomal recessive cardiac valvular form (EDSCV); EDS musculocontractural type (EDSMC); EDS progeroid form (EDSP); Tenascin-X deficiency (TNXD); Brittle cornea syndrome (EDS6B); EDS-like spondylocheiro dysplasia (SCD-EDS)
  • Infantile cortical hyperostosis; Caffey disease
  • Osteogenesis imperfecta
  • Penile cancer
  • Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
COL1A2 and MMP9 collagen type I alpha 2 chain matrix metallopeptidase 9
  • GPVI-mediated activation cascade
  • Collagen degradation
  • Collagen degradation
  • Extracellular matrix organization
  • Collagen biosynthesis and modifying enzymes
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Assembly of collagen fibrils and other multimeric structures
  • Cell surface interactions at the vascular wall
  • Integrin cell surface interactions
  • Integrin cell surface interactions
  • Anchoring fibril formation
  • Crosslinking of collagen fibrils
  • Syndecan interactions
  • Non-integrin membrane-ECM interactions
  • ECM proteoglycans
  • ECM proteoglycans
  • Scavenging by Class A Receptors
  • GP1b-IX-V activation signalling
  • Interleukin-4 and Interleukin-13 signaling
  • Platelet Adhesion to exposed collagen
  • Platelet Adhesion to exposed collagen
  • Platelet Aggregation (Plug Formation)
  • MET activates PTK2 signaling
  • Collagen chain trimerization
  • Signaling by SCF-KIT
  • Collagen degradation
  • Collagen degradation
  • Degradation of the extracellular matrix
  • Degradation of the extracellular matrix
  • Activation of Matrix Metalloproteinases
  • Assembly of collagen fibrils and other multimeric structures
  • EPH-ephrin mediated repulsion of cells
  • Interleukin-4 and Interleukin-13 signaling
  • Neutrophil degranulation
  • Extra-nuclear estrogen signaling
  • Collagenase clostridium histolyticum
  • Glutathione
  • Marimastat
  • Minocycline
  • Captopril
  • Glucosamine
  • Zinc
  • 2-Amino-N,3,3-Trimethylbutanamide
  • 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid
  • AE-941
  • PG-530742
  • 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE
  • (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE
  • (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID
  • Ehlers-Danlos syndrome (EDS), including: EDS classical type (EDS1/2); EDS hypermobility type (EDS3); EDS vascular type (EDS4); EDS kyphoscoliosis type (EDS6); EDS arthrochalasia type (EDS7A/7B); EDS dermatospraxis type (EDS7C); EDS autosomal recessive cardiac valvular form (EDSCV); EDS musculocontractural type (EDSMC); EDS progeroid form (EDSP); Tenascin-X deficiency (TNXD); Brittle cornea syndrome (EDS6B); EDS-like spondylocheiro dysplasia (SCD-EDS)
  • Osteogenesis imperfecta
  • Penile cancer
  • Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
COL2A1 and TGFB1 collagen type II alpha 1 chain transforming growth factor beta 1
  • Collagen degradation
  • Collagen degradation
  • Extracellular matrix organization
  • Collagen biosynthesis and modifying enzymes
  • Signaling by PDGF
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Assembly of collagen fibrils and other multimeric structures
  • Integrin cell surface interactions
  • Integrin cell surface interactions
  • Non-integrin membrane-ECM interactions
  • ECM proteoglycans
  • ECM proteoglycans
  • NCAM1 interactions
  • MET activates PTK2 signaling
  • Collagen chain trimerization
  • Platelet degranulation
  • Influenza Virus Induced Apoptosis
  • Cell surface interactions at the vascular wall
  • Molecules associated with elastic fibres
  • Downregulation of TGF-beta receptor signaling
  • Downregulation of TGF-beta receptor signaling
  • TGF-beta receptor signaling activates SMADs
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • Syndecan interactions
  • ECM proteoglycans
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGFBR1 LBD Mutants in Cancer
  • Transcriptional regulation of white adipocyte differentiation
  • UCH proteinases
  • Interleukin-4 and Interleukin-13 signaling
  • RUNX3 regulates CDKN1A transcription
  • Regulation of RUNX3 expression and activity
  • RUNX3 regulates p14-ARF
  • Collagenase clostridium histolyticum
  • Hyaluronidase
  • Hyaluronidase (Human Recombinant)
  • Type II collagenopathies, including: Achondrogenesis II; Hypochondrogenesis; SED congenita; SMED Strudwick type; Kniest dysplasia; Spondyloperipheral dysplasia; Osteoarthritis with mild chondrodysplasia; Stickler syndrome 1; Platyspondylic skeletal dysplasia, Torrance type; Epiphyseal dysplasia, multiple, with myopia and deafness; Czech dysplasia
  • Vitreoretinal degeneration, including: Stickler syndrome type I (STL1); Stickler syndrome type II (STL2); Snowflake vitreoretinal degeneration (SVD); Wagner syndrome 1 (WGN1); Knobloch syndrome (KNO); Enhanced S-cone syndrome (ESCS); Autosomal dominant vitreoretinochoroidopathy (ADVIRC)
  • Osteoarthritis with mild chondrodysplasia
  • Graft-versus-host disease
  • Allograft rejection
  • Camurati-Engelmann disease; Progressive diaphyseal dysplasia
COL4A1 and MMP9 collagen type IV alpha 1 chain matrix metallopeptidase 9
  • Collagen degradation
  • Collagen degradation
  • Extracellular matrix organization
  • Collagen biosynthesis and modifying enzymes
  • Signaling by PDGF
  • Assembly of collagen fibrils and other multimeric structures
  • Integrin cell surface interactions
  • Integrin cell surface interactions
  • Anchoring fibril formation
  • Crosslinking of collagen fibrils
  • Laminin interactions
  • Laminin interactions
  • Non-integrin membrane-ECM interactions
  • ECM proteoglycans
  • Scavenging by Class A Receptors
  • NCAM1 interactions
  • Collagen chain trimerization
  • Signaling by SCF-KIT
  • Collagen degradation
  • Collagen degradation
  • Degradation of the extracellular matrix
  • Degradation of the extracellular matrix
  • Activation of Matrix Metalloproteinases
  • Assembly of collagen fibrils and other multimeric structures
  • EPH-ephrin mediated repulsion of cells
  • Interleukin-4 and Interleukin-13 signaling
  • Neutrophil degranulation
  • Extra-nuclear estrogen signaling
  • Glutathione
  • Marimastat
  • Minocycline
  • Captopril
  • Glucosamine
  • Zinc
  • 2-Amino-N,3,3-Trimethylbutanamide
  • 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid
  • AE-941
  • PG-530742
  • 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE
  • (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE
  • (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID
  • Brain small vessel disease with Axenfeld-Rieger anomaly
  • Porencephaly
  • Hereditary angiopathy with nephropathy, aneurysms, and muscle cramps (HANAC)
  • Penile cancer
  • Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
COL4A2 and MMP9 collagen type IV alpha 2 chain matrix metallopeptidase 9
  • Collagen degradation
  • Collagen degradation
  • Extracellular matrix organization
  • Collagen biosynthesis and modifying enzymes
  • Signaling by PDGF
  • Assembly of collagen fibrils and other multimeric structures
  • Integrin cell surface interactions
  • Integrin cell surface interactions
  • Anchoring fibril formation
  • Crosslinking of collagen fibrils
  • Laminin interactions
  • Laminin interactions
  • Non-integrin membrane-ECM interactions
  • ECM proteoglycans
  • Scavenging by Class A Receptors
  • NCAM1 interactions
  • Collagen chain trimerization
  • Signaling by SCF-KIT
  • Collagen degradation
  • Collagen degradation
  • Degradation of the extracellular matrix
  • Degradation of the extracellular matrix
  • Activation of Matrix Metalloproteinases
  • Assembly of collagen fibrils and other multimeric structures
  • EPH-ephrin mediated repulsion of cells
  • Interleukin-4 and Interleukin-13 signaling
  • Neutrophil degranulation
  • Extra-nuclear estrogen signaling
  • Glutathione
  • Marimastat
  • Minocycline
  • Captopril
  • Glucosamine
  • Zinc
  • 2-Amino-N,3,3-Trimethylbutanamide
  • 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid
  • AE-941
  • PG-530742
  • 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE
  • (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE
  • (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID
  • Penile cancer
  • Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
COL4A3 and MMP9 collagen type IV alpha 3 chain matrix metallopeptidase 9
  • Collagen degradation
  • Collagen degradation
  • Extracellular matrix organization
  • Collagen biosynthesis and modifying enzymes
  • Signaling by PDGF
  • Assembly of collagen fibrils and other multimeric structures
  • Integrin cell surface interactions
  • Integrin cell surface interactions
  • Anchoring fibril formation
  • Crosslinking of collagen fibrils
  • Laminin interactions
  • Laminin interactions
  • Non-integrin membrane-ECM interactions
  • ECM proteoglycans
  • NCAM1 interactions
  • Collagen chain trimerization
  • Signaling by SCF-KIT
  • Collagen degradation
  • Collagen degradation
  • Degradation of the extracellular matrix
  • Degradation of the extracellular matrix
  • Activation of Matrix Metalloproteinases
  • Assembly of collagen fibrils and other multimeric structures
  • EPH-ephrin mediated repulsion of cells
  • Interleukin-4 and Interleukin-13 signaling
  • Neutrophil degranulation
  • Extra-nuclear estrogen signaling
  • Glutathione
  • Marimastat
  • Minocycline
  • Captopril
  • Glucosamine
  • Zinc
  • 2-Amino-N,3,3-Trimethylbutanamide
  • 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid
  • AE-941
  • PG-530742
  • 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE
  • (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE
  • (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID
  • Benign familial hematuria; Thin basement membrane nephropathy
  • Alport syndrome
  • Penile cancer
  • Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
COL4A4 and MMP9 collagen type IV alpha 4 chain matrix metallopeptidase 9
  • Collagen degradation
  • Collagen degradation
  • Extracellular matrix organization
  • Collagen biosynthesis and modifying enzymes
  • Signaling by PDGF
  • Assembly of collagen fibrils and other multimeric structures
  • Integrin cell surface interactions
  • Integrin cell surface interactions
  • Anchoring fibril formation
  • Crosslinking of collagen fibrils
  • Laminin interactions
  • Laminin interactions
  • Non-integrin membrane-ECM interactions
  • ECM proteoglycans
  • NCAM1 interactions
  • Collagen chain trimerization
  • Signaling by SCF-KIT
  • Collagen degradation
  • Collagen degradation
  • Degradation of the extracellular matrix
  • Degradation of the extracellular matrix
  • Activation of Matrix Metalloproteinases
  • Assembly of collagen fibrils and other multimeric structures
  • EPH-ephrin mediated repulsion of cells
  • Interleukin-4 and Interleukin-13 signaling
  • Neutrophil degranulation
  • Extra-nuclear estrogen signaling
  • Glutathione
  • Marimastat
  • Minocycline
  • Captopril
  • Glucosamine
  • Zinc
  • 2-Amino-N,3,3-Trimethylbutanamide
  • 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid
  • AE-941
  • PG-530742
  • 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE
  • (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE
  • (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID
  • Benign familial hematuria; Thin basement membrane nephropathy
  • Alport syndrome
  • Penile cancer
  • Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
COL4A5 and MMP9 collagen type IV alpha 5 chain matrix metallopeptidase 9
  • Collagen degradation
  • Collagen degradation
  • Extracellular matrix organization
  • Collagen biosynthesis and modifying enzymes
  • Signaling by PDGF
  • Assembly of collagen fibrils and other multimeric structures
  • Integrin cell surface interactions
  • Integrin cell surface interactions
  • Anchoring fibril formation
  • Crosslinking of collagen fibrils
  • Laminin interactions
  • Laminin interactions
  • Non-integrin membrane-ECM interactions
  • ECM proteoglycans
  • NCAM1 interactions
  • Collagen chain trimerization
  • Regulation of expression of SLITs and ROBOs
  • Signaling by SCF-KIT
  • Collagen degradation
  • Collagen degradation
  • Degradation of the extracellular matrix
  • Degradation of the extracellular matrix
  • Activation of Matrix Metalloproteinases
  • Assembly of collagen fibrils and other multimeric structures
  • EPH-ephrin mediated repulsion of cells
  • Interleukin-4 and Interleukin-13 signaling
  • Neutrophil degranulation
  • Extra-nuclear estrogen signaling
  • Glutathione
  • Marimastat
  • Minocycline
  • Captopril
  • Glucosamine
  • Zinc
  • 2-Amino-N,3,3-Trimethylbutanamide
  • 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid
  • AE-941
  • PG-530742
  • 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE
  • (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE
  • (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID
  • Alport syndrome
  • Penile cancer
  • Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
COL4A6 and MMP9 collagen type IV alpha 6 chain matrix metallopeptidase 9
  • Collagen degradation
  • Collagen degradation
  • Extracellular matrix organization
  • Collagen biosynthesis and modifying enzymes
  • Assembly of collagen fibrils and other multimeric structures
  • Integrin cell surface interactions
  • Integrin cell surface interactions
  • Anchoring fibril formation
  • Crosslinking of collagen fibrils
  • Laminin interactions
  • Laminin interactions
  • Non-integrin membrane-ECM interactions
  • ECM proteoglycans
  • Collagen chain trimerization
  • Signaling by SCF-KIT
  • Collagen degradation
  • Collagen degradation
  • Degradation of the extracellular matrix
  • Degradation of the extracellular matrix
  • Activation of Matrix Metalloproteinases
  • Assembly of collagen fibrils and other multimeric structures
  • EPH-ephrin mediated repulsion of cells
  • Interleukin-4 and Interleukin-13 signaling
  • Neutrophil degranulation
  • Extra-nuclear estrogen signaling
  • Glutathione
  • Marimastat
  • Minocycline
  • Captopril
  • Glucosamine
  • Zinc
  • 2-Amino-N,3,3-Trimethylbutanamide
  • 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid
  • AE-941
  • PG-530742
  • 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE
  • (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE
  • (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID
  • Penile cancer
  • Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
CREBBP and MAML2 CREB binding protein mastermind like transcriptional coactivator 2
  • Regulation of gene expression by Hypoxia-inducible Factor
  • RORA activates gene expression
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Transcription and Translation
  • PPARA activates gene expression
  • PPARA activates gene expression
  • Formation of the beta-catenin:TCF transactivating complex
  • Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Transcriptional activation of mitochondrial biogenesis
  • Activation of gene expression by SREBF (SREBP)
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • HATs acetylate histones
  • Attenuation phase
  • Notch-HLH transcription pathway
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • SUMOylation of transcription cofactors
  • Regulation of lipid metabolism by PPARalpha
  • Circadian Clock
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • CD209 (DC-SIGN) signaling
  • TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
  • Activation of the TFAP2 (AP-2) family of transcription factors
  • RUNX1 regulates transcription of genes involved in differentiation of myeloid cells
  • RUNX3 regulates NOTCH signaling
  • RUNX3 regulates NOTCH signaling
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • Estrogen-dependent gene expression
  • TRAF3-dependent IRF activation pathway
  • TRAF6 mediated IRF7 activation
  • FOXO-mediated transcription of cell death genes
  • Regulation of FOXO transcriptional activity by acetylation
  • Regulation of FOXO transcriptional activity by acetylation
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Transcription and Translation
  • Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH2 intracellular domain regulates transcription
  • NOTCH2 intracellular domain regulates transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Notch-HLH transcription pathway
  • RUNX3 regulates NOTCH signaling
  • RUNX3 regulates NOTCH signaling
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • 9-ACETYL-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-1-ONE
  • Rubinstein-Taybi syndrome
CREBBP and TFDP1 CREB binding protein transcription factor Dp-1
  • Regulation of gene expression by Hypoxia-inducible Factor
  • RORA activates gene expression
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Transcription and Translation
  • PPARA activates gene expression
  • PPARA activates gene expression
  • Formation of the beta-catenin:TCF transactivating complex
  • Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Transcriptional activation of mitochondrial biogenesis
  • Activation of gene expression by SREBF (SREBP)
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • HATs acetylate histones
  • Attenuation phase
  • Notch-HLH transcription pathway
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • SUMOylation of transcription cofactors
  • Regulation of lipid metabolism by PPARalpha
  • Circadian Clock
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • CD209 (DC-SIGN) signaling
  • TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
  • Activation of the TFAP2 (AP-2) family of transcription factors
  • RUNX1 regulates transcription of genes involved in differentiation of myeloid cells
  • RUNX3 regulates NOTCH signaling
  • RUNX3 regulates NOTCH signaling
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • Estrogen-dependent gene expression
  • TRAF3-dependent IRF activation pathway
  • TRAF6 mediated IRF7 activation
  • FOXO-mediated transcription of cell death genes
  • Regulation of FOXO transcriptional activity by acetylation
  • Regulation of FOXO transcriptional activity by acetylation
  • Activation of NOXA and translocation to mitochondria
  • Inhibition of replication initiation of damaged DNA by RB1/E2F1
  • Transcription of E2F targets under negative control by DREAM complex
  • Transcription of E2F targets under negative control by DREAM complex
  • Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
  • Activation of PUMA and translocation to mitochondria
  • G0 and Early G1
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Transcription and Translation
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Oxidative Stress Induced Senescence
  • Oncogene Induced Senescence
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • Cyclin E associated events during G1/S transition
  • G1/S-Specific Transcription
  • G1/S-Specific Transcription
  • Cyclin D associated events in G1
  • Cyclin A:Cdk2-associated events at S phase entry
  • Transcriptional Regulation by E2F6
  • Transcriptional regulation of granulopoiesis
  • Transcriptional regulation of granulopoiesis
  • 9-ACETYL-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-1-ONE
  • Rubinstein-Taybi syndrome
CRMP1 and DDX18 collapsin response mediator protein 1 DEAD-box helicase 18
  • CRMPs in Sema3A signaling
HAPLN1 and MMP9 hyaluronan and proteoglycan link protein 1 matrix metallopeptidase 9
  • ECM proteoglycans
  • Signaling by SCF-KIT
  • Collagen degradation
  • Collagen degradation
  • Degradation of the extracellular matrix
  • Degradation of the extracellular matrix
  • Activation of Matrix Metalloproteinases
  • Assembly of collagen fibrils and other multimeric structures
  • EPH-ephrin mediated repulsion of cells
  • Interleukin-4 and Interleukin-13 signaling
  • Neutrophil degranulation
  • Extra-nuclear estrogen signaling
  • Hyaluronic acid
  • Glutathione
  • Marimastat
  • Minocycline
  • Captopril
  • Glucosamine
  • Zinc
  • 2-Amino-N,3,3-Trimethylbutanamide
  • 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid
  • AE-941
  • PG-530742
  • 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE
  • (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE
  • (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID
  • Penile cancer
  • Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
MAPK14 and MITF mitogen-activated protein kinase 14 melanocyte inducing transcription factor
  • NOD1/2 Signaling Pathway
  • p38MAPK events
  • p38MAPK events
  • ERK/MAPK targets
  • Activation of PPARGC1A (PGC-1alpha) by phosphorylation
  • Oxidative Stress Induced Senescence
  • DSCAM interactions
  • ADP signalling through P2Y purinoceptor 1
  • Platelet sensitization by LDL
  • VEGFA-VEGFR2 Pathway
  • activated TAK1 mediates p38 MAPK activation
  • Activation of the AP-1 family of transcription factors
  • KSRP (KHSRP) binds and destabilizes mRNA
  • Myogenesis
  • Myogenesis
  • RHO GTPases Activate NADPH Oxidases
  • Neutrophil degranulation
  • Regulation of TP53 Activity through Phosphorylation
  • CD163 mediating an anti-inflammatory response
  • SUMOylation of transcription factors
  • Dasatinib
  • 4-[5-[2-(1-Phenyl-Ethylamino)-Pyrimidin-4-Yl]-1-Methyl-4-(3-Trifluoromethylphenyl)-1h-Imidazol-2-Yl]-Piperidine
  • N-[(3z)-5-Tert-Butyl-2-Phenyl-1,2-Dihydro-3h-Pyrazol-3-Ylidene]-N'-(4-Chlorophenyl)Urea
  • 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One
  • Inhibitor of P38 Kinase
  • 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine
  • 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine
  • 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea
  • 3-(Benzyloxy)Pyridin-2-Amine
  • 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One
  • 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline
  • 1-(5-Tert-Butyl-2-P-Tolyl-2h-Pyrazol-3-Yl)-3-[4-(2-Morpholin-4-Yl-Ethoxy)-Naphthalen-1-Yl]-Urea
  • 2-Chlorophenol
  • 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole
  • SB220025
  • 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE
  • Triazolopyridine
  • KC706
  • Talmapimod
  • VX-702
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
  • N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide
  • Neflamapimod
  • N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide
  • 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
  • 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE
  • N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
  • 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE
  • 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde
  • N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide
  • N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
  • N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide
  • PH-797804
  • 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine
  • 2-{4-[5-(4-chlorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxoethanol
  • N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA
  • N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE
  • 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide
  • 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
  • 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA
  • 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM
  • 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE
  • N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide
  • N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide
  • N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide
  • 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine
  • 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE
  • 4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE
  • 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE
  • Ocular albinism; Ocular albinism, type I (OA1); Waardenburg syndrome, type II (WS2-OA)
  • Waardenburg syndrome (WS)
  • Malignant melanoma
MAPK14 and GATA3 mitogen-activated protein kinase 14 GATA binding protein 3
  • NOD1/2 Signaling Pathway
  • p38MAPK events
  • p38MAPK events
  • ERK/MAPK targets
  • Activation of PPARGC1A (PGC-1alpha) by phosphorylation
  • Oxidative Stress Induced Senescence
  • DSCAM interactions
  • ADP signalling through P2Y purinoceptor 1
  • Platelet sensitization by LDL
  • VEGFA-VEGFR2 Pathway
  • activated TAK1 mediates p38 MAPK activation
  • Activation of the AP-1 family of transcription factors
  • KSRP (KHSRP) binds and destabilizes mRNA
  • Myogenesis
  • Myogenesis
  • RHO GTPases Activate NADPH Oxidases
  • Neutrophil degranulation
  • Regulation of TP53 Activity through Phosphorylation
  • CD163 mediating an anti-inflammatory response
  • Ub-specific processing proteases
  • Interleukin-4 and Interleukin-13 signaling
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • Estrogen-dependent gene expression
  • Factors involved in megakaryocyte development and platelet production
  • Dasatinib
  • 4-[5-[2-(1-Phenyl-Ethylamino)-Pyrimidin-4-Yl]-1-Methyl-4-(3-Trifluoromethylphenyl)-1h-Imidazol-2-Yl]-Piperidine
  • N-[(3z)-5-Tert-Butyl-2-Phenyl-1,2-Dihydro-3h-Pyrazol-3-Ylidene]-N'-(4-Chlorophenyl)Urea
  • 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One
  • Inhibitor of P38 Kinase
  • 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine
  • 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine
  • 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea
  • 3-(Benzyloxy)Pyridin-2-Amine
  • 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One
  • 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline
  • 1-(5-Tert-Butyl-2-P-Tolyl-2h-Pyrazol-3-Yl)-3-[4-(2-Morpholin-4-Yl-Ethoxy)-Naphthalen-1-Yl]-Urea
  • 2-Chlorophenol
  • 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole
  • SB220025
  • 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE
  • Triazolopyridine
  • KC706
  • Talmapimod
  • VX-702
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
  • N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide
  • Neflamapimod
  • N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide
  • 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
  • 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE
  • N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
  • 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE
  • 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde
  • N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide
  • N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
  • N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide
  • PH-797804
  • 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine
  • 2-{4-[5-(4-chlorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxoethanol
  • N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA
  • N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE
  • 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide
  • 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
  • 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA
  • 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM
  • 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE
  • N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide
  • N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide
  • N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide
  • 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine
  • 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE
  • 4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE
  • 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE
CST6 and TGFB1 cystatin E/M transforming growth factor beta 1
  • Platelet degranulation
  • Influenza Virus Induced Apoptosis
  • Cell surface interactions at the vascular wall
  • Molecules associated with elastic fibres
  • Downregulation of TGF-beta receptor signaling
  • Downregulation of TGF-beta receptor signaling
  • TGF-beta receptor signaling activates SMADs
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • Syndecan interactions
  • ECM proteoglycans
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGFBR1 LBD Mutants in Cancer
  • Transcriptional regulation of white adipocyte differentiation
  • UCH proteinases
  • Interleukin-4 and Interleukin-13 signaling
  • RUNX3 regulates CDKN1A transcription
  • Regulation of RUNX3 expression and activity
  • RUNX3 regulates p14-ARF
  • Hyaluronidase
  • Hyaluronidase (Human Recombinant)
  • Graft-versus-host disease
  • Allograft rejection
  • Camurati-Engelmann disease; Progressive diaphyseal dysplasia
CTBP1 and MAML2 C-terminal binding protein 1 mastermind like transcriptional coactivator 2
  • Deactivation of the beta-catenin transactivating complex
  • SUMOylation of transcription cofactors
  • Repression of WNT target genes
  • TCF7L2 mutants don't bind CTBP
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Transcription and Translation
  • Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH2 intracellular domain regulates transcription
  • NOTCH2 intracellular domain regulates transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Notch-HLH transcription pathway
  • RUNX3 regulates NOTCH signaling
  • RUNX3 regulates NOTCH signaling
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • Formic Acid

Page 15 out of 43 pages